Progesterone (CIDR, PRID, Eazi-Breed)

Progesterone delivered via controlled internal drug release (CIDR) devices represents one of the most significant advances in cattle reproductive management technology, providing sustained release of natural progesterone through intravaginal administration. These devices contain pharmaceutical-grade progesterone incorporated into a silicone matrix that releases hormone at controlled rates when inserted in the vagina, maintaining blood progesterone concentrations that mimic the luteal phase of the estrous cycle. The CIDR technology enables precise manipulation of reproductive cycles in both cycling and non-cycling cattle, forming the foundation of modern estrus synchronization and timed artificial insemination programs.

The mechanism of action of intravaginal progesterone devices involves continuous absorption of progesterone through the vaginal mucosa into systemic circulation, establishing and maintaining elevated blood progesterone levels that suppress the hypothalamic-pituitary-gonadal axis similar to the natural luteal phase. This exogenous progesterone prevents the preovulatory luteinizing hormone (LH) surge necessary for ovulation, effectively synchronizing follicular waves and preventing estrus expression during the treatment period. Unlike synthetic progestins, the natural progesterone in CIDR devices is metabolically identical to endogenous hormone, minimizing concerns about tissue residues and supporting the relatively short withdrawal periods established for these products.

The controlled internal drug release device for cattle typically contains 1.38 grams of progesterone in a T-shaped silicone elastomer body designed for comfortable retention in the bovine vagina. The device includes a nylon tail for retrieval and maintains constant drug release throughout the typical 7-day insertion period. Similar devices have been developed for sheep (CIDR-G containing 0.3 grams progesterone) and goats, with appropriate sizing and drug loading for each species. The PRID (Progesterone Releasing Intravaginal Device) represents an alternative design incorporating a stainless steel spiral covered with progesterone-containing silicone, providing similar hormonal effects through a different physical configuration.

Regulatory approval for intravaginal progesterone devices in the United States covers synchronization of estrus in beef cattle, dairy heifers, and lactating dairy cows, with separate approvals for sheep applications. The FDA has established a zero-day meat withdrawal and zero-hour milk discard for CIDR devices when used according to label directions, reflecting the rapid clearance of natural progesterone following device removal. This favorable regulatory status supports broad application in commercial cattle operations where timed breeding programs require precise cycle manipulation without extended withdrawal periods that would complicate marketing or milk production schedules.

The primary indication for CIDR devices in cattle involves synchronization of estrus to enable efficient breeding management through artificial insemination or controlled natural service programs. By establishing uniform progestational states across groups of cattle and then removing devices simultaneously, producers achieve tight clustering of estrus expression that allows concentrated labor deployment for heat detection and insemination. This synchronization capability transforms reproductive management from reactive heat detection throughout extended breeding seasons to proactive timed breeding events that improve AI pregnancy rates and shorten calving intervals.

Treatment of anestrus represents a critical application of intravaginal progesterone devices in cattle experiencing prolonged postpartum intervals or seasonal reproductive quiescence. The exogenous progesterone priming provided by CIDR insertion can initiate cyclicity in non-cycling cattle by establishing the progestational environment necessary for normal estrous cycle initiation. When combined with GnRH and prostaglandin in protocols like CO-Synch + CIDR, these devices enable successful breeding of anestrous cattle that would otherwise require extended waiting periods or remain non-productive throughout the breeding season.

Timed artificial insemination programs rely heavily on CIDR technology to achieve precise ovulation timing that enables fixed-time AI without heat detection. Protocols such as the 7-day CO-Synch + CIDR program position ovulation within predictable windows following device removal and hormone administration, allowing insemination at predetermined times regardless of behavioral estrus expression. These fixed-time AI programs achieve pregnancy rates comparable to or exceeding natural service while providing the genetic advancement and disease control benefits of artificial insemination without the labor demands of conventional heat detection.

Embryo transfer programs utilize CIDR devices to synchronize recipient cattle for embryo receipt at appropriate stages of their artificial cycles. The precise cycle control achievable with progesterone devices enables tight matching of embryo developmental stage with recipient uterine environment, optimizing conditions for embryo survival and pregnancy establishment. Recipients typically receive CIDR treatment followed by protocols that position them for embryo transfer 7 days after synchronized ovulation, when the uterine environment best supports transferred embryos.

Specialized applications of intravaginal progesterone devices include management of certain reproductive abnormalities and support of early pregnancy in high-risk situations. Some practitioners utilize CIDR devices to provide progesterone supplementation in cattle with suspected luteal insufficiency or those with history of early embryonic loss. While evidence for efficacy in these applications remains limited, the theoretical basis for progestational support during early pregnancy has prompted investigation of supplemental progesterone strategies. Research continues to define appropriate patient selection and treatment protocols for these therapeutic applications.

The standard cattle CIDR device contains 1.38 grams of progesterone incorporated into the silicone elastomer body, delivering approximately 0.5 to 0.6 grams of progesterone during typical 7-day insertion periods. This drug loading provides blood progesterone concentrations of approximately 4 to 6 ng/mL during the treatment period, sufficient to suppress LH release and maintain a functional progestational state. The remaining progesterone in removed devices should not be reused due to reduced drug content and potential contamination concerns, though some research has investigated efficacy of once-used CIDRs for specific applications.

Sheep and goat CIDR devices contain reduced progesterone loads appropriate for smaller species, typically 0.3 grams for the CIDR-G design. These smaller devices also feature appropriately sized physical dimensions for retention in the ovine and caprine vagina. Dosing in small ruminants follows label directions for the species-specific device, with insertion periods typically ranging from 5 to 14 days depending on the synchronization protocol employed and species-specific reproductive physiology.

Administration of CIDR devices requires proper technique to ensure comfortable insertion, adequate retention, and easy retrieval. The device should be loaded into the appropriate insertion tool with the wings folded together and the tail extending through the opening. Following sanitary preparation of the vulva, the loaded applicator is inserted through the vulvar lips at an upward angle (approximately 45 degrees in standing cattle) and advanced until the device is deposited in the anterior vagina. Proper placement positions the device cranial to the cervix with wings deployed laterally and tail extending caudally through the vulva.

Insertion duration for CIDR devices varies according to the synchronization protocol employed, ranging from 5 to 14 days depending on program design and intended outcomes. The standard 7-day CO-Synch + CIDR protocol in cattle uses 7-day insertion, while modified protocols may employ shorter or longer durations. Precise timing of insertion and removal according to protocol specifications is critical for achieving desired synchronization, and deviation from scheduled timing can significantly compromise program outcomes.

Device removal requires gentle traction on the nylon tail to withdraw the device from the vagina, ideally performed with the animal properly restrained in a chute or handling facility. The tail should be grasped firmly and steady downward traction applied while an assistant monitors for unusual resistance that might indicate adhesions or improper positioning. Following removal, visual inspection of the device confirms complete retrieval and notes any abnormal discharge that might indicate vaginitis or other complications. Removed devices should be disposed according to label directions rather than discarded in areas accessible to other animals.

Withdrawal times for CIDR devices reflect the rapid clearance of natural progesterone from the body following device removal. The FDA-established withdrawal for cattle is zero days for meat and zero hours for milk, meaning animals may be slaughtered or milk may be marketed immediately following device removal when used according to label directions. This favorable withdrawal status supports application in lactating dairy cattle without milk discard requirements, though some protocols incorporating other drugs (GnRH, prostaglandins) may have withdrawal times associated with those components that must be observed.

CIDR devices generally demonstrate excellent tolerability in cattle populations when inserted and managed according to recommended protocols, with most animals completing treatment periods without significant complications. The most common observation during CIDR treatment is the expected suppression of estrous behavior, which represents the intended pharmacological effect rather than an adverse reaction. Some cattle may exhibit mild restlessness or discomfort immediately following insertion, typically resolving within 24 hours as the animal adapts to the device presence.

Vaginal irritation and discharge represent the most frequently observed local effects of CIDR device insertion, occurring in varying degrees across treated populations. Mild mucoid discharge is common and typically not clinically significant, representing normal vaginal secretions accumulating around the foreign body. More significant mucopurulent discharge may develop in some animals, particularly with extended insertion periods or in cattle with pre-existing vaginal contamination. This discharge typically resolves spontaneously following device removal without requiring specific treatment, though severe cases warrant veterinary evaluation.

Vaginitis of varying severity affects a small percentage of CIDR-treated cattle, characterized by vaginal inflammation, purulent discharge, and potential systemic effects in severe cases. Risk factors for vaginitis include prolonged insertion duration, contaminated devices or insertion technique, pre-existing reproductive tract infections, and individual animal susceptibility. Monitoring for excessive discharge, vulvar swelling, or systemic illness during the treatment period enables early identification of animals requiring device removal and veterinary attention.

Device loss occurs in a percentage of treated cattle, with reported retention rates typically exceeding 95 percent but varying based on insertion technique, device design, and animal factors. Lost devices may pass unnoticed if animals are not closely monitored, resulting in unsynchronized cycles that reduce program efficiency. Animals losing devices before scheduled removal may require prostaglandin treatment to induce luteolysis if corpus luteum formation has occurred, or may be bred on subsequent natural cycles rather than the synchronized cohort.

Rare complications of CIDR device use include vaginal adhesions, cervical trauma from improper insertion technique, and allergic reactions to device components. Vaginal adhesions may develop with extended insertion periods or following significant vaginitis, potentially complicating future breeding or calving. Cervical damage from overly aggressive insertion is preventable with proper technique emphasizing gentle advancement at appropriate angles. True allergic reactions to the silicone elastomer or progesterone are extremely rare but should be considered in animals demonstrating unexpected systemic responses to device insertion.

CIDR devices are contraindicated in cattle with active reproductive tract infections including vaginitis, cervicitis, metritis, or pyometra, as device insertion may exacerbate existing infections and compromise treatment outcomes. Animals presenting with purulent vaginal discharge, uterine enlargement, or systemic signs of reproductive tract infection should receive appropriate treatment and recovery time before consideration for CIDR-based synchronization programs. Insertion of foreign devices into infected reproductive tracts risks worsening infections and creating conditions favorable for bacterial proliferation.

Pregnant animals should not receive CIDR devices due to the potential for pregnancy disruption from device insertion and the questionable value of progestational supplementation in normally progressing pregnancies. While CIDR-delivered progesterone would theoretically support pregnancy maintenance, the physical presence of the device and insertion process poses unnecessary risks. Cattle should be confirmed non-pregnant through examination or adequate intervals following previous breeding before CIDR insertion, with particular attention to valuable animals where pregnancy status may be uncertain.

Animals with known hypersensitivity to progesterone or silicone materials should not receive CIDR treatment, though such sensitivities are rarely documented. Previous adverse reactions to CIDR devices including severe vaginitis or apparent allergic responses should prompt careful evaluation before retreatment, with consideration of alternative synchronization approaches that avoid intravaginal progesterone delivery. Medical records should document any previous complications to inform future reproductive management decisions.

Structural abnormalities of the vagina or cervix may contraindicate CIDR device use if they prevent proper insertion, positioning, or retention of the device. Animals with vaginal strictures, adhesions from previous injuries, or cervical abnormalities may be unsuitable candidates for intravaginal device protocols. Pre-insertion examination when abnormalities are suspected enables identification of cattle requiring alternative synchronization approaches rather than risking device-related complications.

CIDR devices are intentionally combined with gonadotropin-releasing hormone (GnRH) products in the majority of modern synchronization protocols, representing complementary rather than problematic interactions. The combination of CIDR-delivered progesterone with GnRH administration at insertion and/or removal creates the hormonal sequences necessary for follicular wave synchronization and timed ovulation. These combinations (CO-Synch + CIDR, 7-day protocols) represent standard of care for cattle synchronization and have been extensively validated for safety and efficacy.

Prostaglandin interactions with CIDR progesterone follow predictable physiological patterns that form the basis of synchronization protocol design. Prostaglandins administered during CIDR treatment cause luteolysis of any corpus luteum present, while the exogenous progesterone maintains the progestational state until device removal. This combination enables synchronization of cattle regardless of their stage of the estrous cycle at treatment initiation, as the CIDR provides progestational support independent of endogenous luteal function. Prostaglandins administered at or near CIDR removal ensure luteolysis in cattle that may have formed corpora lutea during treatment.

Estradiol products, where approved, may be combined with CIDR protocols to enhance follicular wave synchronization and improve protocol outcomes. Estradiol benzoate or estradiol cypionate administration at specific protocol timepoints promotes follicular turnover and enhances the precision of ovulation timing following CIDR removal. However, estradiol products are not approved for use in cattle in the United States, limiting their application to research settings and jurisdictions with different regulatory frameworks. Protocols designed for US application rely on GnRH rather than estradiol for follicular manipulation.

Interactions between CIDR treatment and other reproductive interventions including embryo transfer and fixed-time AI follow protocol-specific timing requirements rather than pharmacokinetic drug interactions. The timing of AI or embryo transfer relative to CIDR removal and associated hormone treatments is critical for optimal outcomes and must follow validated protocol specifications. Deviation from established timing compromises synchronization precision and reduces pregnancy rates regardless of the specific products employed.

Human safety precautions during CIDR device handling require attention to minimize hormone exposure, particularly for pregnant women or individuals with hormone-sensitive conditions. Personnel should wear gloves when handling devices to prevent dermal progesterone absorption, and hands should be washed thoroughly after handling even when gloves are worn. Pregnant women should avoid handling CIDR devices whenever possible due to theoretical concerns regarding exogenous progesterone exposure. Accidental skin contact with progesterone-containing surfaces should prompt immediate washing of affected areas.

Food safety considerations for CIDR progesterone devices benefit from the favorable regulatory status established for these products when used according to label directions. The zero-day meat withdrawal and zero-hour milk discard reflect rapid progesterone clearance and absence of tissue residue concerns with natural progesterone. However, compliance with label directions is essential, and operations modifying protocols or using devices in non-approved applications should consult veterinary guidance regarding appropriate withdrawal period assignments.

Environmental considerations for CIDR devices include proper disposal of used devices and packaging materials. Used devices contain residual progesterone that could affect non-target organisms and should not be discarded in areas accessible to animals or in standard waste streams. Manufacturer disposal recommendations typically include return programs or disposal as pharmaceutical waste. The silicone elastomer body is not biodegradable and represents a persistent environmental material requiring appropriate disposal management.

Infection control precautions during CIDR insertion and removal minimize vaginitis risk and support program success. Sanitary preparation of the perineal area before insertion reduces introduction of environmental contaminants into the vagina. Applicators should be cleaned or replaced between animals, and gloves should be changed or hands washed between cattle to prevent cross-contamination. Animals with obvious vulvar contamination or vaginal discharge should be evaluated before device insertion and may require postponement of treatment until sanitary insertion conditions can be established.

Proper technique precautions during insertion prevent trauma and optimize device retention. Excessive force during insertion can damage vaginal or cervical tissues, while inadequate advancement may result in improper positioning and early device loss. Personnel should be trained in proper insertion technique before handling cattle independently, and facilities should provide adequate restraint to enable controlled, deliberate device placement without animal movement that could cause injury.

Storage requirements for CIDR devices include maintenance in original sealed packaging at controlled room temperature, protected from excessive heat and direct sunlight that could degrade the progesterone or alter silicone elastomer properties. The individual packaging provides protection from contamination and physical damage that could compromise device integrity. Devices should remain sealed until immediately before use, and any devices with damaged packaging should be discarded rather than inserted to prevent contamination-related complications.

Inventory management for CIDR devices should ensure adequate supplies for planned synchronization programs while minimizing waste from expiration. Shelf life for properly stored devices typically extends several years from manufacture, with expiration dates printed on individual packages. Rotation of inventory on a first-in, first-out basis ensures older stock is used before newer purchases. Operations should verify expiration dates before large synchronization events and dispose of expired devices rather than risking compromised drug delivery from degraded products.

Disposal of used CIDR devices requires attention to both the pharmaceutical content and the non-biodegradable physical structure. Used devices contain residual progesterone (typically 30-40% of original load) and should not be discarded in general waste or areas where other animals might contact them. Some manufacturers offer return programs for used devices, while other disposal options include incineration at licensed facilities or disposal as pharmaceutical waste according to local regulations. The silicone body will not degrade in landfills and represents persistent material requiring appropriate long-term disposal planning.

Species-specific considerations for intravaginal progesterone devices recognize the different device designs developed for cattle versus small ruminants. The standard cattle CIDR contains 1.38 grams progesterone in a body sized for the bovine vagina, while sheep and goat devices (CIDR-G) contain 0.3 grams in smaller physical dimensions appropriate for ovine and caprine anatomy. Using species-appropriate devices ensures proper fit, retention, and drug delivery for each species. Cattle devices should not be used in small ruminants, and vice versa, due to size mismatch and inappropriate drug loading.

Breed sensitivities to CIDR treatment have not been extensively documented across cattle breeds, with the devices approved for use across the diverse populations encountered in beef and dairy operations. Bos indicus breeds and their crosses may demonstrate different reproductive responses to synchronization protocols compared to Bos taurus cattle, potentially requiring protocol modifications for optimal results. These differences relate more to underlying reproductive physiology than specific CIDR sensitivity, but breed should be considered when selecting synchronization approaches and evaluating program outcomes.

Production type considerations differentiate CIDR applications between beef and dairy cattle operations, though the devices are approved for both. Dairy operations benefit from the zero-hour milk discard status that enables CIDR use in lactating cows without production interruption, while beef operations appreciate the flexibility of synchronizing both cycling and anestrous cattle. Protocol selection may differ between production types based on handling frequency, facility design, and breeding program objectives, but the core CIDR technology applies across production systems.

Age and reproductive status considerations influence CIDR protocol selection and expected outcomes. Heifers typically demonstrate higher synchronization precision and pregnancy rates compared to postpartum cows, reflecting their cyclic status and absence of lactational anestrus. Postpartum cows, particularly those in negative energy balance or with extended anestrous intervals, may require CIDR-based protocols specifically designed to address non-cycling status. Young heifers approaching puberty may be induced to cycle with CIDR treatment, though appropriate body condition and development should be confirmed before initiating breeding programs in young animals.

Same-class alternatives to CIDR devices include the PRID (Progesterone Releasing Intravaginal Device), which delivers progesterone through a different physical design utilizing a stainless steel spiral covered with progesterone-containing silicone. The PRID achieves similar physiological outcomes through the same mechanism of vaginal progesterone absorption, though handling characteristics and retention properties differ somewhat from CIDR devices. Selection between CIDR and PRID may reflect availability, cost, practitioner preference, or specific protocol requirements rather than significant efficacy differences.

Different mechanism alternatives for estrus synchronization include feed-delivered progestins such as melengestrol acetate (MGA), which achieves progestational effects through oral rather than intravaginal administration. MGA offers convenience for feedlot operations with established feeding programs but lacks the precision of CIDR-based protocols for timed AI applications. Injectable progestins represent another alternative, though injection-based progestational treatments are less common than device-based or oral approaches in modern cattle reproductive management.

Combination protocol components that complement CIDR devices include GnRH products (gonadorelin, buserelin), prostaglandins (dinoprost, cloprostenol), and human chorionic gonadotropin (hCG) in specific applications. These products combine with CIDR treatment in comprehensive synchronization protocols that address follicular dynamics, corpus luteum management, and ovulation timing. Selection among available products and protocol designs should consider specific operation requirements, cattle population characteristics, and breeding program objectives. Veterinary consultation supports appropriate protocol selection and implementation for optimal reproductive program outcomes.